Two women with their head down talking and a man on the left side of the photo. His face is cropped

Facilities and services

  • We specialise in early clinical trials of study drugs for pharmaceutical and biotechnology companies worldwide.
  • Founded in 1993, HMR is now the biggest CRO of its kind in the UK and one of the biggest in Europe.
  • We have 270 staff, including a resident 24/7 resuscitation team, extensive purpose-built facilities, 145 beds, and on-site pharmacy, radiopharmacy, and laboratory.
  • We can provide a full service from design to clinical study report, all in one building in London, UK.
  • Our level of service and commitment is the same for all companies, regardless of size.
  • HMR has: MHRA Phase 1 Accreditation for FIH trials; Manufacturing and Import Licence for study drugs [MIA(IMP)]; Home Office licence for all controlled drug substances; and Environment Agency licence for trials of radiolabelled study drugs.
  • Our Quality System is compliant with ISO 9001, our Laboratory with ISO 17025, and our Information Security Management System with ISO 27001.
  • We’ve won three Queen’s Awards for Exports or Enterprise, the most prestigious of UK business awards.

Learn more
Hospital care with patients in bed and three consultants/nurses taking care of them

Our experience

  • We have completed >900 trials for pharmaceutical and biotechnology companies from 23 countries worldwide, including all 15 major companies by revenue, and >200 small-to-medium sized or virtual companies.
  • We can do almost all types of trial, from simple bioequivalent to complex trials, such as endoscopy, sleep, radiopharmacy, bridging, QTc, and PET, fMRI or CT imaging.
  • Many of our trials are first-in-human (FIH) and proof-of-concept in design and range from small to large and complex trials with adaptive protocol and several parts.
  • Most of the study drugs are small molecules, but we also do many trials of biological products, such as recombinant proteins, monoclonal antibodies, vaccines, and small interfering RNA molecules.
  • Most of our trials are in healthy subjects, but many include patients with the target disease; some trials involve only patients.
  • We have a large database of healthy subjects of all ages and ethnicities, and many types of patient.
  • We collaborate with London universities, hospitals, and general practices for trials requiring patients.

Learn more
Three women doctors smiling

Why choose HMR?

  • We don’t have a business development team. We rely solely on reputation, recommendations, record, and repeat business, a unique testament to the quality of our services.
  • The UK is a good place to do clinical trials: the regulatory system is rigorous, efficient, and supportive of clinical pharmacology and sponsors and can help sponsors to plan their FIH trials.
  • The MHRA and FDA inspectors have never reported any important GCP or GMP findings.
  • Our pharmacy prepares and QP releases all types of dose. Our laboratory provides rapid turnaround of safety samples, and a wide range of biomarkers, such as flow cytometry, cytokine, coagulation, platelet aggregation, and PCR tests.
  • We developed TOPS, a database to register participants in UK phase 1 trials; use is now mandatory for regulatory approval of phase 1 trials.
  • We PCR test all subjects for SARS-Cov-2, and admit only negative subjects. We PCR test all front-line staff regularly. So far we’ve kept the virus out of our trials.
  • Together with sponsors, we publish results of our trials in peer-reviewed journals.

Learn more